

SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 peptide (South Africa variant) (STJ506307)

GENERAL INFORMATION

Product Type Biomolecules

 Short
 SARS CoV-2 Spike Glycoprotein South Africa variant Positive Control for STJ506303 is synthetically produced from the 400-450 sequence about the South Africa variant and is suitable for use in western blot applications.

 Applications
 WB

 Host/Source
 Reactivity

PRODUCT PROPERTIES

Clonality Clone ID Concentration Conjugation Purification Dilution Range Formulation

tion Provided as 100 uL ready-to-use, in SDS-PAGE sample buffer (Laemelli's buffer) containing Tris, pH 6.8, 1 % SDS, Glycerol and Bromophenolblue blue as tracking dye. The sample is reduced by adding 2% beta mercaptoethanol. The protein concentration is

Isotype Storage Store Instruction

Storage Store at-20°C for long term storage. Avoid freeze-thaw cycles.

TARGET INFORMATION

Gene ID Gene Symbol Uniprot ID Immunogen 400-450 Immunogen 400-450 Region Specificity This is participation

This is positive control is recommended for use in combination with SARS CoV-2 Spike Glycoprotein South Africa variant antibody STJ506303.

Immunogen Sequence

This product is suitable for in-vitro studies under the RESEARCH USE ONLY [RUO] licence. This product must not be used as for diagnostic or other medical purposes. St John's Laboratory Ltd, Knowledge Dock Business Centre, University Way, London, E16 2RD | Tel: 0208 223 3081